Tag: oncofetal protein

Data from the dose escalation portion of the Phase 1/2 study of JK06 in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, is being presented at the European Society for Medical Oncology (ESMO) Congress, being held October 17 - 21, 2025, in Berlin, Germany.[1]

Clinical-stage biotechnology company Oncternal Therapeutics announced the closing of an $18.4 million Series B financing. The company which develops first-in-class and novel therapies for...